Short-and long-term efficacy of combined cabergoline and octreotide treatment in controlling IGF-I levels in acromegaly

Neuroendocrinology

Volumn 92, Issue 2, 2010, Pages 120-127

  Mattar, Priscilla ^a   Alves Martins, Manoel Ricardo ^a   Abucham, Julio ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Acromegaly; Cabergoline; Prolactin

Indexed keywords

CABERGOLINE; GROWTH HORMONE; OCTREOTIDE; PROLACTIN; SOMATOMEDIN C;

ACROMEGALY; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG WITHDRAWAL; EVENING DOSAGE; FEMALE; GROWTH HORMONE BLOOD LEVEL; HUMAN; MALE; OPEN STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT RESPONSE;

ACROMEGALY; ADULT; AGED; DOPAMINE AGONISTS; DRUG THERAPY, COMBINATION; ERGOLINES; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MIDDLE AGED; OCTREOTIDE; SOMATOSTATIN;

EID: 78649524272     PISSN: 00283835     EISSN: None     Source Type: Journal    
DOI: 10.1159/000317314     Document Type: Article

References (27)

1. Melmed S, Ho K, Klibanski A, Reichlin S, Thorner M: Recent advances in pathogenesis, diagnosis and management of acromegaly. J Clin Endocrinol Metab 1995;80:3395-3402.
2. Holdaway IM, Rajasoorya RC, Gamble GD: Factors inf luencing mortality in acromegaly. J Clin Endocrinol Metab 2004;89:667-674.
3. Chanson P, Salenave S: Acromegaly. Orphanet J Rare Dis 2008;3:17.
4. Alexander L, Appleton D, Hall R, Ross WM, Wilkinson R: Epidemiology of acromegaly in the Newcastle region. Clin Endocrinol (Oxf) 1980;12:71-94.
5. Melmed S, Colao A, Barkan AL, et al: Guidelines for acromegaly management: an update. J Clin Endocrinol Metab 2009;94:1509-1517.
6. Freda PU: Somatostatin analogs in acromega ly. J Clin Endocrinol Metab 2002;87:3013-3018.
7. Lombardi G, Galdiero M, Auriemma RS, Pivonello R, Colao A: Acromegaly and the cardiovascular system. Neuroendocrinology 2006;83:211-217.
8. Melmed S: Acromegaly. N Engl J Med 2006;355:2558-2573.
9. Jaffe CA, Barkan AL: Treatment of acromegaly with dopamine agonists. Endocrinol Metab Clin North Am 1992;21:713-735.
10. Freda PU: How effective are current therapies for acromegaly? Growth Horm IGF Res 2003;13(Suppl A): S144-S151.
11. Moyes VJ, Metcalfe KA, Drake WM: Clinical use of cabergoline as primary and adjunctive treatment for acromegaly. Eur J Endocrinol 2008;159:541-545.
12. Rains CP, Bryson HM, Fitton A: Cabergoline: a review of its pharmacological properties and therapeutic potential in the treatment of hyperprolactinaemia and inhibition of lactation. Drugs 1995;49:255-279.
13. Trainer PJ, Drake WM, Katznelson L, et al: Treatment of acromegaly with the growthhormone receptor antagonist pegvisomant. N Engl J Med 2000;342:1171-1177.
14. Marzullo P, Ferone D, Di Somma C, et al: Efficacy of combined treatment with lanreotide and cabergoline in select therapy-resistant acromegalic patients. Pituitary 1999;1:115-120.
15. Jallad RS, Bronstein MD: Optimizing medical therapy of acromegaly: beneficial effects of cabergoline in patients uncontrolled with long-acting release octreotide. Neuroendocrinology 2009;90:82-92.
16. Gatta B, Hau DH, Catargi B, Roger P, Tabarin A: Re-evaluation of the efficacy of the association of cabergoline to somatostatin analogues in acromegalic patients. Clin Endocrinol 2005;63:477-481.
17. Cozzi R, Attanasio R, Lodrini S, Lasio G: Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients: efficacy of predictive value of prolactin status. Clin Endocrinol 2004;61:209-215.
18. Selvarajah D, Webster J, Ross R, Newell-Price J: Effectiveness of adding dopamine agonist therapy to long-acting somatostatin analogues in the management of acromegaly. Eur J Endocrinol 2005:569-574.
19. Webb SM: Quality of life in acromegaly. Neuroendocrinology 2006;83:224-229.
20. Flogstad AK, Halse J, Grass P, et al: A Comparison of octreotide, bromocriptine, or a combination of both drugs in acromegaly. J Clin Endocrinol Metab 1994;79:461-465.
21. Abs R, Verhelst J, Maiter D, et al: Cabergoline in the treatment of acromegaly: a study in 64 patients. J Clin Endocrinol Metab 1998;83:374-378.
22. Valassi E, Klibanski A, Biller B M K: Potencial cardiac valve effects of dopamine agonists in hyperprolactinemia. J Clin Endocrinol Metab 2010;95:1025-1033.
23. Rocheville M, Lange DC, Kumar U, Sasi R, Patel RC, Patel YC: Subtypes of the somatostatin receptor assemble as functional homo-heterodimers. J Biol Chem 2000;275:7862-7869.
24. Rocheville M, Lange DC, Kumar U, Patel SC, Patel RC, Patel YC: Receptors for dopamine and somatostatin: formation of heterooligomers with enhanced functional activity. Science 2000;288:154-157.
25. Jaquet P, Gunz G, Saveanu A, et al: BIM-23A760, a chimeric molecule directed towards somatostatin and dopamine receptors, vs. universal somatostatin receptors ligands in GH-secreting pituitary adenomas partial responders to octreotide. J Endocrinol Invest 2005;28(11 Suppl International): 21-27.
26. Jaquet P, Gunz G, Saveanu A, et al: Efficacy of chimeric molecules directed towards multiple somatostatin and dopamine receptors on inhibition of GH and prolactin secretion from GH-secreting pituitary adenomas classified as partially responsive to somatostatin analog therapy. Eur J Endocrinol 2005;153:135-141.
27. Saveanu A, Lavaque, Gunz G, et al: Demonstration of enhanced potency of a chimeric somatostatin-dopamine molecule, BIM-23A387, in supressing growth hormone and prolactin secretion from human pituitary somatotroph adenoma cells. J Clin Endocrinol Metab 2002;87:5545-5552.